The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Abbott Laboratories missed on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue improved and earnings per share increased.
Margins improved across the board.
Abbott Laboratories notched revenue of $10.4 billion. The 18 analysts polled by S&P Capital IQ predicted revenue of $10.6 billion. Sales were 4.1% higher than the prior-year quarter's $10.0 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions.
Non-GAAP EPS came in at $1.45. The 21 earnings estimates compiled by S&P Capital IQ predicted $1.44 per share on the same basis. GAAP EPS of $1.02 for Q4 were 11% higher than the prior-year quarter's $0.92 per share.
Source: S&P Capital IQ. Quarterly periods. Figures may be non-GAAP to maintain comparability with estimates.
For the quarter, gross margin was 63.0%, 470 basis points better than the prior-year quarter. Operating margin was 23.9%, 360 basis points better than the prior-year quarter. Net margin was 15.6%, 110 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $9.6 billion. On the bottom line, the average EPS estimate is $1.02.
Next year's average estimate for revenue is $40.7 billion. The average EPS estimate is $5.02.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 2,555 members out of 2,648 rating the stock outperform, and 93 members rating it underperform. Among 726 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 709 give Abbott Laboratories a green thumbs-up, and 17 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Abbott Laboratories is hold, with an average price target of $58.24.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Abbott Laboratories. Learn how to maximize your investment income and "Secure Your Future With 11 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Abbott Laboratories to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool owns shares of Abbott Laboratories. Motley Fool newsletter services have recommended buying shares of Abbott Laboratories. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.